Hayashida, Tetsu

写真a

Affiliation

School of Medicine, Department of Surgery (General and Gastroenterological Surgery) (Shinanomachi)

Position

Assistant Professor/Senior Assistant Professor

Related Websites

External Links

Career 【 Display / hide

  • 1998.05
    -
    Present

    慶應義塾大学医学部, 外科学, 研修医

  • 2000.05
    -
    Present

    慶應義塾大学医学部, 外科学, 助手(専修医)

  • 2001.05
    -
    Present

    慶應義塾大学医学部, 外科学, 助手

  • 2005.05
    -
    2008.05

    Harvard medical school & Massachusetts General Hospital, Department of Surgery, Cancer center, Research fellow

  • 2008.06
    -
    Present

    慶應義塾大学医学部, 外科学, 助教

display all >>

Academic Background 【 Display / hide

  • 1992.04
    -
    1998.03

    Keio University, 医学部

    University, Graduated

Academic Degrees 【 Display / hide

  • 博士(医学), 慶應義塾大学, 2007

    ドメイン内插入融合蛋白(FGF-RNase fused protein)による3次元培養モデルにおける血管新生阻害効果

Licenses and Qualifications 【 Display / hide

  • 医師免許, 1998.05

  • 日本外科学会専門医, 2004.12

  • 日本がん治療認定医機構癌治療認定医, 2014.04

  • 日本乳癌学会認定位, 2014.04

  • 日本乳がん検診精度管理中央機構 検診マンモグラフィー読影認定医(A), 2015.06

display all >>

 

Research Areas 【 Display / hide

  • General surgery

Research Keywords 【 Display / hide

  • Breast cancer

  • Breast surgery

 

Papers 【 Display / hide

  • A first Japanese case of neuroendocrine prostate cancer accompanied by lung and brain metastasis with somatic and germline BRCA2 mutation.

    Kosaka T, Hongo H, Aimono E, Matsumoto K, Hayashida T, Mikami S, Nishihara H, Oya M

    Pathology international 69 ( 12 ) 715 - 720 2019.12

    Research paper (scientific journal), Joint Work, Accepted,  ISSN  1320-5463

  • Intensive optimization and evaluation of global DNA methylation quantification using LC-MS/MS.

    Nakagawa T, Wakui M, Hayashida T, Nishime C, Murata M

    Analytical and bioanalytical chemistry 411 ( 27 ) 7221 - 7231 2019.10

    Research paper (scientific journal), Joint Work, Accepted,  ISSN  1618-2642

  • Magnetically Promoted Rapid Immunofluorescence Staining for Frozen Tissue Sections

    Onishi T., Matsuda S., Nakamura Y., Kuramoto J., Tsuruma A., Sakamoto S., Suzuki S., Fuchimoto D., Onishi A., Chikaki S., Kaneko M., Kuwahata A., Sekino M., Yasuno H., Hanyu N., Kurita T., Takei H., Sakatani T., Taruno K., Nakamura S., Hayashida T., Jinno H., Kusakabe M., Handa H., Kameyama K., Kitagawa Y.

    Journal of Histochemistry and Cytochemistry (Journal of Histochemistry and Cytochemistry)  67 ( 8 ) 575 - 587 2019.08

    Research paper (scientific journal), Joint Work, Accepted,  ISSN  00221554

     View Summary

    © The Author(s) 2019. Current immunohistochemistry methods for diagnosing abnormal cells, such as cancer cells, require multiple steps and can be relatively slow compared with intraoperative frozen hematoxylin and eosin staining, and are therefore rarely used for intraoperative examination. Thus, there is a need for novel rapid detection methods. We previously demonstrated that functionalized fluorescent ferrite beads (FF beads) magnetically promoted rapid immunoreactions. The aim of this study was to improve the magnetically promoted rapid immunoreaction method using antibody-coated FF beads and a magnet subjected to a magnetic field. Using frozen sections of xenograft samples of A431 human epidermoid cancer cells that express high levels of epidermal growth factor receptor (EGFR) and anti-EGFR antibody-coated FF beads, we reduced the magnetically promoted immunohistochemistry procedure to a 1-min reaction and 1-min wash. We also determined the optimum magnetic force for the antibody reaction (from 7.79 × 10−15 N to 3.35 × 10−15 N) and washing (4.78 × 10−16 N), which are important steps in this technique. Furthermore, we stained paraffin-embedded tissue arrays and frozen sections of metastatic breast cancer lymph nodes with anti-pan-cytokeratin antibody-coated FF beads to validate the utility of this system in clinical specimens. Under optimal conditions, this ultra-rapid immunostaining method may provide an ancillary method for pathological diagnosis during surgery. (J Histochem Cytochem 58:XXX–XXX, 2010).

  • Optimal use of anthracycline-free perioperative chemotherapy in HER2-positive breast cancer patients

    Watanuki R., Hayashida T., Kawai Y., Kikuchi M., Nakashoji A., Yokoe T., Toyota T., Seki T., Takahashi M., Kitagawa Y.

    International Journal of Clinical Oncology (International Journal of Clinical Oncology)  24 ( 7 ) 807 - 814 2019.07

    Research paper (scientific journal), Joint Work, Accepted,  ISSN  13419625

     View Summary

    © 2019, Japan Society of Clinical Oncology. Purpose: In adjuvant settings of human epidermal growth factor receptor 2 (HER2)-positive breast cancer, anthracycline-based chemotherapy followed by taxane and trastuzumab is a standard regimen. Recent studies have reported the use of anthracycline-free adjuvant chemotherapy in selected HER2-positive breast cancer patients. We conducted a single-center retrospective study to identify the characteristics of HER2-positive breast cancer patients for whom anthracyclines can be safely omitted. Methods: A total of 238 women were diagnosed with HER2-positive breast cancer and treated with neoadjuvant and/or adjuvant chemotherapy between January 1, 2008 and December 31, 2015 at Keio University Hospital. They were divided in two cohorts: an “anthracycline” cohort of 112 anthracycline-treated women and a “no anthracycline” cohort of 126 anthracycline-untreated women. Survival outcomes were estimated by Kaplan–Meier method. Results: The 3-year disease-free survival rates in the no-anthracycline and anthracycline cohorts were 91.3% and 93.1%, respectively (P = 0.692). After using a statistical method with inverse probability of treatment weighting to minimize the selection bias, no significant differences were observed between the two cohorts (adjusted hazard ratio for disease-free survival: 1.042; P = 0.909). Stratified by tumor size, no significant differences were observed between the two cohorts in the cT1N0 and cT2N0 subsets (P = 0.516 and P = 0.579, respectively). The recurrence rate was low among patients who achieved pathological complete response after receiving neoadjuvant chemotherapy with or without anthracyclines. Conclusion: Our study suggests that anthracyclines can be safely omitted in selected patients with HER2-positive breast cancer, who have cT1N0 or cT2N0 and achieved pathological complete response after receiving neoadjuvant chemotherapy.

  • Effectiveness of Antiemetic Regimens for Highly Emetogenic Chemotherapy-Induced Nausea and Vomiting: A Systematic Review and Network Meta-Analysis

    Yokoe T., Hayashida T., Nagayama A., Nakashoji A., Maeda H., Seki T., Takahashi M., Takano T., Abe T., Kitagawa Y.

    Oncologist (Oncologist)  24 ( 6 ) e347 - e357 2019.06

    Research paper (scientific journal), Joint Work, Accepted,  ISSN  10837159

     View Summary

    © AlphaMed Press 2018 Background: It is important to control chemotherapy-induced nausea and vomiting (CINV) to maintain dose intensity and patients' quality of life. The National Comprehensive Cancer Network guidelines suggest combination therapy of antiemetic agents. The growing number of antiemetic regimens, and in particular the growing use of regimens containing antagonists to the Nk-1 receptor (NK1RAs) and the antipsychotic drug olanzapine (OLZ), call for the re-evaluation of the optimal regimen for CINV. This study assessed the efficacy and safety of antiemetic regimens for highly emetogenic chemotherapy, using Bayesian network meta-analysis. Methods: Randomized trials that compared different antiemetic regimens were included. We strictly followed Preferred Reporting Items for Systematic Reviews and Meta-Analysis guidelines. The main outcomes were the odds ratio (OR) for overall complete response (absence of vomiting). We conducted network meta-analysis within a Bayesian model to combine the direct and indirect evidence. Safety was assessed from the trial description. All statistical tests were two-sided. Results: We systematically reviewed 27 randomized control trials (13,356 participants), which compared 12 different antiemetic regimens: serotonin-3 receptor antagonist (5HT3), 5HT3 + dexamethasone (Dex), palonosetron (PAL), PAL + Dex, PAL at 0.75 mg (PAL0.75), PAL0.75 + Dex, NK1RA + 5HT3 + Dex, NK1RA + PAL + Dex, an oral combination of netupitant and palonosetron (NEPA) + Dex, OLZ + 5HT3 + Dex, OLZ + PAL + Dex, and OLZ + NK1RA + 5HT3 + Dex. An NK1RA + 5HT3 + Dex regimen and an NK1RA + palonosetron + Dex regimen gave a higher complete response (CR) rate than the reference regimen, 5HT3 + Dex (OR, 1.75; 95% credibility interval [95% CrI], 1.56–1.97, and OR, 2.25; 95% CrI, 1.66–3.03, respectively). A regimen containing NEPA was more effective in producing CR than conventional regimens without NEPA or olanzapine. Further analysis, based on the surface under the cumulative ranking probability curve, indicated that olanzapine-containing regimens were the most effective in producing CR. Conclusion: Our meta-analysis supports the conclusion that olanzapine-containing regimens are the most effective for CINV of highly emetogenic chemotherapy. We confirmed that NK1RA + PAL + Dex is the most effective of conventional regimens. Substituting olanzapine for an Nk-1 receptor antagonist may offer a less costly and more effective alternative for patients. Implications for Practice: Nausea and vomiting during chemotherapy often pose difficulties for patients and doctors, making it hard to continue the proper therapy and to maintain the quality of life. This article gives insights into the optimal choice of medicine to treat nausea during chemotherapy. The findings reported here provide readers with a robust efficacy ranking of antinausea medicine, which can be used as a reference for the best possible treatment. Furthermore, the 70% less costly drug, olanzapine, is suggested to be equally effective to aprepitant in reducing nausea and vomiting. The possibility of offering a cost-effective treatment to a wider range of the population is discussed.

display all >>

Papers, etc., Registered in KOARA 【 Display / hide

display all >>

Reviews, Commentaries, etc. 【 Display / hide

  • 【いまだからこそ見直される乳房温存手術】傍乳輪wave-like incisionと全乳房皮下剥離を併用した整容性の高い乳房温存手術

    菊池 雅之, 林田 哲, 北川 雄光

    手術 (金原出版(株))  73 ( 12 ) 1659 - 1666 2019.11

    Research paper, Joint Work,  ISSN  0037-4423

  • 【がん遺伝子パネル検査の現状と展望】クリニカルシークエンスの現状と未来

    山口 茂夫, 林田 哲, 北川 雄光

    乳癌の臨床 ((株)篠原出版新社)  34 ( 5 ) 385 - 393 2019.10

    Research paper, Joint Work,  ISSN  0911-2251

  • 【がん診療Update】乳癌 進行再発乳がんに対するこれからの化学療法の役割

    林田 哲

    クリニシアン (エーザイ(株))  66 ( 2-3 ) 195 - 199 2019.03

    Research paper, Joint Work,  ISSN  0387-1541

  • 手術のtips and pitfalls 乳がん手術における後出血防止の工夫と出血時の対応

    林田 哲, 北川 雄光

    日本外科学会雑誌 ((一社)日本外科学会)  120 ( 1 ) 65 - 67 2019.01

    Research paper, Joint Work,  ISSN  0301-4894

  • 【がん診療における心血管合併症:onco-cardiologyアップデート】内科で診る機会の多い腫瘍の化学療法と心血管合併症について知る 乳癌

    林田 哲, 北川 雄光

    診断と治療 ((株)診断と治療社)  106 ( 8 ) 967 - 972 2018.08

    Research paper, Joint Work,  ISSN  0370-999X

     View Summary

    <Headline>1 乳癌は過去30年間一貫して増加の一途を辿り、女性における部位別罹患率は第1位である。2 根治可能な早期乳癌と、根治は望めない進行再発乳癌において、治療戦略は明確に異なる。3 乳癌はその生物学的な特徴から複数のサブタイプ分類がなされ、各サブタイプにおいて予後や使用する薬剤が異なる。4 頻用される薬剤による心毒性の特徴は、アントラサイクリン系薬剤においては用量依存性・不可逆性・予後不良である一方、抗HER2薬においては用量非依存性・可逆的で重篤な心疾患症状を呈することは少ない。(著者抄録)

display all >>

Presentations 【 Display / hide

  • 肝癌に対する凍結融解壊死療(Cryoablation)

    Akatsu Tomotaka, Wakabayashi Gou, Tanabe Minoru, Ueda Masakazu, Shimazu Motohide, Aiura Kouichi, Kawachi Shigeyuki, Yoshida Masashi, Takigawa Yutaka, Hashimoto Takeo, Matsuura Yoshifumi, Abe Yuuta, Kido Hiromu, Hayashida Tetsu, Yagi Hiroshi, Itou Yasuhiro, Miyata Ryouhei, Kitajima Masaki

    第26回慶應外科フォーラム総会, 2003.01, Oral Presentation(general)

  • 当科における肝細胞癌に対する生体部分肝移植

    Akatsu Tomotaka, Shimazu Motohide, Wakabayashi Gou, Tanabe Minoru, Hoshino Ken, Kawachi Shigeyuki, Yoshida Masashi, Watanabe Toshihiko, Shibutani Shintarou, Hashimoto Takeo, Takigawa Yutaka, Shimojima Naoki, Abe Yuuta, Kaneda Munehisa, Kido Hiromu, Shintani Tsunehiro, Hayashida Tetsu, Yagi Hiroshi, Akiyoshi Takurin, Itou Yasuhiro, Inoue Fumihiko, Miyata Ryouhei, Morikawa Yasuhide, Kitajima Masaki

    第26回慶應外科フォーラム総会, 2003.01, Oral Presentation(guest/special)

  • c-kit陽性GISTに対しメシル酸イマチニブが著効を認めた1症例

    Hayashida Tetsu, Ueda Masakazu, Kawachi Shigeyuki, Tanabe Minoru, Aiura Kouichi, Wakabayashi Gou, Ootani Yoshihide, Shimazu Motohide, Kubota Tetsurou, Kitajima Masaki

    第64回日本臨床外科学会総会, 2002.11, Oral Presentation(general)

  • 非機能性膵内分泌腫瘍9例の検討

    Hayashida Tetsu, Aiura Kouichi, Itou Yasuhiro, Hashimoto Takeo, Kawachi Shigeyuki, Tanabe Minoru, Wakabayashi Gou, Shimazu Motohide, Ueda Masakazu, Kitajima Masaki

    第64回日本臨床外科学会総会, 2002.11, Oral Presentation(general)

  • 非機能性膵内分泌腫瘍9例の検討

    Hayashida Tetsu, Aiura Kouichi, Itou Yasuhiro, Hashimoto Takeo, Kawachi Shigeyuki, Tanabe Minoru, Wakabayashi Gou, Shimazu Motohide, Ueda Masakazu, Kitajima Masaki

    第64回日本臨床外科学会総会, 2002.11, Oral Presentation(general)

display all >>

Research Projects of Competitive Funds, etc. 【 Display / hide

  • 人工知能による乳房超音波診断支援システムの精度向上と実用化の検討

    2020.04
    -
    2023.03

    MEXT,JSPS, Grant-in-Aid for Scientific Research, 林田 哲, Grant-in-Aid for Scientific Research (C), Principal Investigator

  • HOXB9 expression in breast cancer predicts efficacy of bevacizumab treatment

    2014.04
    -
    2017.03

    MEXT,JSPS, Grant-in-Aid for Scientific Research, 林田 哲, Grant-in-Aid for Scientific Research (C), Principal Investigator

     View Summary

    Homeobox B9 (HOXB9), a transcriptional factor, regulates developmental processes and tumor progression and has recently been recognized as a strong angiogenic factor in breast cancer progresson. This study aimed to investigate the role of HOXB9 in tumorigenesis and angiogenesis. Bevacizumab, an anti-VEGF antibody, remarkably suppressed tumor proliferation by inhibiting angiogenesis in HOXB9-overexpressing xenografts. HOXB9 promotes the secretion of angiogenic factors, including VEGF, to induce tumor proliferation through microenvironmental communication via IL6 signaling; moreover, silencing of VEGF or IL6 terminates microenvironmental crosstalk. Thus, HOXB9 and IL6 may be surrogate markers for bevacizumab treatment in breast cancer.

Awards 【 Display / hide

  • The 8th International Symposium On Cancer Research and Therapy, Subsidy Award

    2013.11

  • 第51回日本癌治療学会 最優秀演題賞

    2013.10, 日本癌治療学会

  • 第22回広島がんセミナー 最優秀演題賞

    2011.10

  • 第19回日本がん転移学会学術総会 最優秀演題賞

    2011.06, 日本がん転移学会

 

Courses Taught 【 Display / hide

  • LECTURE SERIES, SURGERY

    2021

  • PATHOPHYSIOLOGY FOR ACUTE CARE

    2020

  • LECTURE SERIES, SURGERY

    2020

  • LECTURE SERIES, SURGERY

    2019

  • PATHOPHYSIOLOGY FOR ACUTE CARE

    2019